{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:36:44Z","timestamp":1760834204305,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.trim.2022.101743","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T06:19:28Z","timestamp":1668147568000},"page":"101743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion"],"prefix":"10.1016","volume":"76","author":[{"given":"Yutong","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaodong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trim.2022.101743_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.trim.2022.101743_bb0010","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-21-0301","article-title":"60 years young: the evolving role of allogeneic hematopoietic stem cell transplantation in cancer immunotherapy","volume":"81","author":"Cieri","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.trim.2022.101743_bb0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/bmt.2016.283","article-title":"Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation","volume":"52","author":"Ma","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.trim.2022.101743_bb0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00277-017-2960-7","article-title":"Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"Mo","year":"2017","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.trim.2022.101743_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/107327480200900205","article-title":"Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation","volume":"9","author":"Luznik","year":"2002","journal-title":"Cancer Control: J. Moffitt Cancer Cent."},{"issue":"5","key":"10.1016\/j.trim.2022.101743_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.20.01719","article-title":"Defining the role of donor lymphocyte infusion in high-risk hematologic malignancies","volume":"39","author":"Schmid","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.trim.2022.101743_bb0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15881","article-title":"G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients","volume":"186","author":"Schneidawind","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2022.101743_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211043748","article-title":"Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome","volume":"12","author":"Park","year":"2021","journal-title":"Ther. Adv. Hematol."},{"issue":"19","key":"10.1016\/j.trim.2022.101743_bb0045","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.trim.2022.101743_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/bmt.2014.223","article-title":"Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome","volume":"50","author":"Mo","year":"2015","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.trim.2022.101743_bb0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.10570","article-title":"Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation","volume":"92","author":"Huang","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.trim.2022.101743_bb0060","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","first-page":"177","article-title":"GVHD prophylaxis (Immunosuppression)","author":"Michonneau","year":"2019"},{"issue":"20","key":"10.1016\/j.trim.2022.101743_bb0065","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.3760\/cma.j.issn.0366-6999.20141481","article-title":"Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant","volume":"127","author":"Yan","year":"2014","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.trim.2022.101743_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjh.16190","article-title":"Advances in understanding the pathogenesis of graft-versus-host disease","volume":"187","author":"Robert","year":"2019","journal-title":"British journal of haematology"},{"issue":"14","key":"10.1016\/j.trim.2022.101743_bb0075","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-019-01174-1","article-title":"Janus kinase inhibition for graft-versus-host disease: current status and future prospects","volume":"79","author":"Mannina","year":"2019","journal-title":"Drugs."},{"issue":"1","key":"10.1016\/j.trim.2022.101743_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.trim.2022.101743_bb0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.trim.2022.101743_bb0090","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.trim.2022.101743_bb0095","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.trim.2022.101743_bb0100","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2020007336","article-title":"Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness","volume":"136","author":"Mohty","year":"2020","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.trim.2022.101743_bb0105","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.trim.2022.101743_bb0110","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.trim.2022.101743_bb0115","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","article-title":"Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation","volume":"25","author":"Abedin","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.trim.2022.101743_bb0120","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.2011.589383","article-title":"A potential role of ruxolitinib in leukemia","volume":"20","author":"Naqvi","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.trim.2022.101743_bb0125","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5306\/wjco.v7.i5.414","article-title":"Bone and soft tissue tumors presenting as sciatic notch dumbbell masses: a critical differential diagnosis of sciatica","volume":"7","author":"Matsumoto","year":"2016","journal-title":"World J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.trim.2022.101743_bb0130","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","volume":"23","author":"Yan","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.trim.2022.101743_bb0135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"7","key":"10.1016\/j.trim.2022.101743_bb0140","first-page":"529","article-title":"Zhonghua","volume":"41","author":"Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (III) -acute graft-versus-host disease","year":"2020","journal-title":"xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"5","key":"10.1016\/j.trim.2022.101743_bb0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Saad","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.trim.2022.101743_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbmt.2003.11.002","article-title":"Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia","volume":"10","author":"Nordlander","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"year":"2007","series-title":"Treatment of Donor Stem Cell Infusion for Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation-One Case Report and Literature Review","author":"YJJOCH","key":"10.1016\/j.trim.2022.101743_bb0155"},{"issue":"3","key":"10.1016\/j.trim.2022.101743_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.transci.2010.03.011","article-title":"Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation","volume":"42","author":"Yegin","year":"2010","journal-title":"Transf. Apheres. Sci."},{"issue":"6","key":"10.1016\/j.trim.2022.101743_bb0165","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","article-title":"JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML","volume":"130","author":"Karjalainen","year":"2017","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.trim.2022.101743_bb0170","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1038\/leu.2013.197","article-title":"JAK inhibitors suppress t(8;21) fusion protein-induced leukemia","volume":"27","author":"Lo","year":"2013","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.trim.2022.101743_bb0175","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.trim.2022.101743_bb0180","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.trim.2022.101743_bb0185","article-title":"Ruxolitinib combined with corticosteroids as first-line therapy for acute graft-versus-host disease in Haploidentical peripheral blood stem cell transplantation recipients","volume":"27(1):75.e1-.e10","author":"Hou","year":"2021","journal-title":"Transplant. Cell. Ther."},{"issue":"7","key":"10.1016\/j.trim.2022.101743_bb0190","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/ctr.12561","article-title":"Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT","volume":"29","author":"Yan","year":"2015","journal-title":"Clin. Transpl."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:01:59Z","timestamp":1760810519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422002179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":38,"alternative-id":["S0966327422002179"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101743","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101743"}}